

ViroGates announces the launch of suPARnostic® TurbiLatex on all commercially relevant Roche Diagnostics cobas instruments

ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems, primarily for emergency departments in hospitals, today announces that it has completed the development and regulatory approval of its suPARnostic® TurbiLatex product for Roche Diagnostics cobas c 500 and 700 series. The c 500 and 700 series are the market leading instruments for performing immunochemical analysis in the hospitals across Europe.

ViroGates' suPARnostic® TurbiLatex product can now be implemented on big modular systems in the central laboratories in the hospitals. According to Roche Diagnostics, more than 20,000 cobas instruments are installed worldwide, each with a throughput volume of up to 1,000 tests per hour.

suPARnostic® TurbiLatex enables automatic handling of blood samples at clinical chemistry laboratories and is thus a pivotal element in the company's European expansion strategy with special focus on the acute care market, valued at approximately 1 billion Euro annually for the suPARnostic® analysis.

CEO Jakob Knudsen, says in a comment: *"With this launch, we have completed our development work for now for the cobas instruments from Roche Diagnostics, since all commercially relevant instruments within the Roche Diagnostic cobas series will now be able to run suPARnostic® TurbiLatex tests. Many potential customers have enquired about the availability of suPARnostic® for the cobas instruments since it requires no manual handling and offers seamless transfer of laboratory results to the medical departments of the hospitals. Most laboratories can now use their standard equipment to analyze patient samples using suPARnostic® TurbiLatex. We believe this will facilitate implementation of suPAR analysis at the hospitals and thereby strengthen our sales efforts."*

About the turbidimetric measurement principle: The TurbiLatex product is based on a technology called turbidimetry that measures the loss of intensity of transmitted light due to the scattering effect of particles suspended in the blood sample. The principle of measuring blood samples by using turbidimetry is very important in relation to immunoassays, as it is the basis for almost all central laboratory clinical chemistry instrument platforms in hospitals. suPARnostic® TurbiLatex is a particle-enhanced turbidimetric assay.

For further information contact:

CEO Jakob Knudsen

Tel. (+45) 2113 1336, Email: jk@virogates.com

ViroGates A/S

CVR-nr. 25734033, Blokken 45, DK-340 Birkerød

www.virogates.com

Certified Advisor

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se

About ViroGates

ViroGates is an international Medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic® measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic® Quick Triage and TurbiLatex test, hospital staff will get answers in just 20 minutes. The prognostic value of suPARnostic® is validated by more than 550 clinical trials and studies which included more than 300,000 blood samples.